Pheochromocytomas and Paragangliomas (PCPG) are rare neuroendocrine tumors that arise from adrenal glands or nerve tissues. They often cause excess hormone production, leading to symptoms like high blood pressure, headaches, and sweating. Early diagnosis and treatment are crucial to manage symptoms and prevent complications.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Incident Cases of PCPG
</li>
<li dir="ltr" aria-level="1">
Occurrence or Absence of mutation in PCPG
</li>
<li dir="ltr" aria-level="1">
Age-Specific Cases of PCPG
</li>
<li dir="ltr" aria-level="1">
Stage-Specific Cases of PCPG
</li>
</ul>
<h3 dir="ltr">Pheochromocytomas and Paragangliomas Epidemiology</h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, ~5K new PCPG cases were reported in the 7MM, with numbers expected to rise.
</li>
<li dir="ltr" aria-level="1">
Around 75% of US cases involve germline or somatic mutations.
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK had 1.8K new PCPG cases in 2024.
</li>
<li dir="ltr" aria-level="1">
Germany recorded the highest PCPG cases in EU4 and the UK, Spain the lowest in 2024.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market">Pheochromocytomas and Paragangliomas Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The 7MM PCPG market was valued at ~USD 310 million in 2024, with expected growth through 2034.
</li>
<li dir="ltr" aria-level="1">
The US PCPG market stood at USD 189 million in 2024, projected to rise with new therapies.
</li>
<li dir="ltr" aria-level="1">
In 2024, Japan&rsquo;s MIBG market led with approximately USD 9.4 million.
</li>
</ul>
<h3 dir="ltr">Pheochromocytomas and Paragangliomas Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Increasing incidence and diagnosis rates of PCPG.
</li>
<li dir="ltr" aria-level="1">
Advancements and launches of novel targeted therapies.
</li>
<li dir="ltr" aria-level="1">
Growing awareness and genetic testing for germline mutations.
</li>
</ul>
<h3 dir="ltr">Pheochromocytomas and Paragangliomas Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Limited treatment options for advanced or metastatic cases.
</li>
<li dir="ltr" aria-level="1">
High cost and limited accessibility of emerging therapies.
</li>
<li dir="ltr" aria-level="1">
Challenges in early diagnosis due to disease rarity and nonspecific symptoms.
</li>
</ul>
<h3 dir="ltr">Pheochromocytomas and Paragangliomas Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
ONC201 (DORDAVIPRONE)
</li>
<li dir="ltr" aria-level="1">
WELIREG (BELZUTIFAN)
</li>
<li dir="ltr" aria-level="1">
LUTATHERA (LUTETIUM [177LU] OXODOTREOTIDE/DOTATATE)
</li>
<li dir="ltr" aria-level="1">
VMT-??-NET
</li>
</ul>
<h3 dir="ltr">Pheochromocytomas and Paragangliomas Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Chimerix
</li>
<li dir="ltr" aria-level="1">
Ohara Pharmaceutical
</li>
<li dir="ltr" aria-level="1">
Merck
</li>
<li dir="ltr" aria-level="1">
Novartis
</li>
<li dir="ltr" aria-level="1">
Perspective Therapeutics
</li>
</ul>
And others.

Pheochromocytomas and Paragangliomas Market Infographics

Pheochromocytomas and Paragangliomas Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape